Drugs & Targets Pangea Biomed, OHSU Knight Cancer Institute collaborate to improve cancer therapy precision November 01, 2024Vol.50 No.41
Drugs & Targets FDA approves Vyloy+chemo for gastric or GEJ junction adenocarcinoma with CLDN18.2-positive tumors October 25, 2024Vol.50 No.40
Drugs & Targets FDA accepts NDA, grants priority review for Pixclara glioma imaging agent October 25, 2024Vol.50 No.40
Drugs & Targets EC approves Keytruda combinations for endometrial carcinoma indication, FIGO 2014 stage III-IVA locally advanced cervical cancer October 25, 2024Vol.50 No.40
Drugs & Targets EMA CHMP grants positive opinion of Korjuny for malignant ascites October 25, 2024Vol.50 No.40
Drugs & Targets EMA CHMP issues positive opinions for Tevimbra for gastric or GEJ adenocarcinoma and ESCC October 25, 2024Vol.50 No.40
Drugs & Targets EMA accepts marketing application for AVT03, a proposed biosimilar to Prolia and Xgeva October 18, 2024Vol.50 No.39
Drugs & Targets Jaguar Health launches FDA-approved treatment for “chemo mouth” October 18, 2024Vol.50 No.39
Drugs & Targets FDA approves inavolisib + palbociclib + fulvestrant for endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer October 11, 2024Vol.50 No.38
Drugs & Targets FDA clears the way for multi-center investigator-initiated study of Alpha DaRT in immunocompromised patients with recurrent cSCC October 11, 2024Vol.50 No.38
